Literature DB >> 29534171

Burden of cardiovascular risk factors and cardiovascular disease in childhood cancer survivors: data from the German CVSS-study.

J Faber1, A Wingerter1, M A Neu1, N Henninger1, S Eckerle1, T Münzel2,3, K J Lackner4, M E Beutel5, M Blettner6, W Rathmann7, A Peters8,9,10, C Meisinger9,11, B Linkohr9, H Neuhauser12,13, P Kaatsch14, C Spix14, A Schneider6, H Merzenich6, M Panova-Noeva15,16, J H Prochaska3,15,16,17, P S Wild3,15,16,17.   

Abstract

Aims: The cardiac and vascular late sequelae in long-term survivors of childhood cancer (CVSS)-study aimed to quantify the prevalence of cardiovascular risk factors (CVRF) and cardiovascular disease (CVD) in German childhood cancer survivors (CCS). Methods and results: In the CVSS-study (NCT02181049), 1002 CCS (age range 23-48 years) diagnosed with neoplasia prior to 15 years of age between 1980 and 1990 prospectively underwent a systematic, standardized clinical and laboratory cardiovascular screening, identical to the population-based Gutenberg Health Study (GHS) cohort. For 951 individuals, prevalences of CVRF and CVD were primarily compared to the GHS sample and to two further German population-based cohorts. Using log-binomial regression models, an increased risk for occurrence of arterial hypertension [relative risk (RR) 1.38, 95% confidence interval (95% CI 1.21-1.57)] and dyslipidaemia [RR 1.26 (95% CI 1.12-1.42)] was found. This indicates a premature occurrence compared to the general population of approximately 6 and 8 years, respectively [rate advancement period estimator, RAPhypertension 5.75 (95% CI 3.5-8.0) and RAPdyslipidaemia 8.16 (95% CI 4.4-11.9)]. Overall, no differences were observed for obesity and diabetes. Overt CVD was present in 4.5% (95% CI 3.0-6.6%) of CCS [RR 1.89 (95% CI 1.34-2.66), RAPCVD 7.9 (95% CI 4.1-11.7)], of which the most frequent entities were congestive heart failure and venous thromboembolism. Prevalences of CVRF and CVD increased with age without reaching a plateau over time.
Conclusion: This large CCS screening examination revealed consistently in comparison to three population samples a considerably increased risk for premature CVD. The findings in these young adult CCS indicate a high burden of cardiovascular morbidity and mortality in the long term. Clinicaltrials. gov-Nr: NCT02181049.

Entities:  

Mesh:

Year:  2018        PMID: 29534171     DOI: 10.1093/eurheartj/ehy026

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  26 in total

Review 1.  Doxorubicin-Induced Cardiomyopathy in Children.

Authors:  Trevi R Mancilla; Brian Iskra; Gregory J Aune
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

2.  Letter to the Editor: Re: "Is heart rate variability a valuable method to investigate cardiac autonomic dysfunction in subjects with leukemia? A systematic review to evaluate its importance in clinical practice" by Kirizawa et al.

Authors:  Maxime Caru; Daniel Curnier
Journal:  Support Care Cancer       Date:  2019-10-29       Impact factor: 3.603

3.  Doxorubicin treatments induce significant changes on the cardiac autonomic nervous system in childhood acute lymphoblastic leukemia long-term survivors.

Authors:  Maxime Caru; Denis Corbin; Delphine Périé; Valérie Lemay; Jacques Delfrate; Simon Drouin; Laurence Bertout; Maja Krajinovic; Caroline Laverdière; Gregor Andelfinger; Daniel Sinnett; Daniel Curnier
Journal:  Clin Res Cardiol       Date:  2019-02-18       Impact factor: 5.460

4.  The 6-minute walk test is a good predictor of cardiorespiratory fitness in childhood cancer survivors when access to comprehensive testing is limited.

Authors:  David Mizrahi; Joanna E Fardell; Richard J Cohn; Robyn E Partin; Carrie R Howell; Melissa M Hudson; Leslie L Robison; Kirsten K Ness; Jamie McBride; Penelope Field; Claire E Wakefield; David Simar
Journal:  Int J Cancer       Date:  2019-12-17       Impact factor: 7.396

Review 5.  Cardio-toxicity in childhood cancer survivors "Cure is not enough".

Authors:  Ulrich Neudorf; Anne Schönecker; Dirk Reinhardt
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 6.  Molecular mechanisms and cardiovascular implications of cancer therapy-induced senescence.

Authors:  Ibrahim Y Abdelgawad; Karim T Sadak; Diana W Lone; Mohamed S Dabour; Laura J Niedernhofer; Beshay N Zordoky
Journal:  Pharmacol Ther       Date:  2020-12-01       Impact factor: 12.310

7.  Status and predictors of planning ability in adult long-term survivors of CNS tumors and other types of childhood cancer.

Authors:  Mareike Ernst; Ana N Tibubos; Josef Unterrainer; Juliane Burghardt; Elmar Brähler; Philipp S Wild; Claus Jünger; Jörg Faber; Astrid Schneider; Manfred E Beutel
Journal:  Sci Rep       Date:  2019-05-13       Impact factor: 4.379

8.  Sodium and Potassium Intakes and Cardiovascular Risk Profiles in Childhood Cancer Survivors: The SCCSS-Nutrition Study.

Authors:  Fabiën N Belle; Christina Schindera; Idris Guessous; Maja Beck Popovic; Marc Ansari; Claudia E Kuehni; Murielle Bochud
Journal:  Nutrients       Date:  2019-12-24       Impact factor: 5.717

9.  Promotion of Arterial Stiffness by Childhood Cancer and Its Characteristics in Adult Long-Term Survivors.

Authors:  Natalie Arnold; Hiltrud Merzenich; Arthur Wingerter; Andreas Schulz; Astrid Schneider; Jürgen H Prochaska; Sebastian Göbel; Marie A Neu; Nicole Henninger; Marina Panova-Noeva; Susan Eckerle; Claudia Spix; Irene Schmidtmann; Karl J Lackner; Manfred E Beutel; Norbert Pfeiffer; Thomas Münzel; Jörg Faber; Philipp S Wild
Journal:  J Am Heart Assoc       Date:  2021-02-24       Impact factor: 5.501

10.  Prevalence of mental distress among adult survivors of childhood cancer in Germany-Compared to the general population.

Authors:  Juliane Burghardt; Eva Klein; Elmar Brähler; Mareike Ernst; Astrid Schneider; Susan Eckerle; Marie Astrid Neu; Arthur Wingerter; Nicole Henninger; Marina Panova-Noeva; Jürgen Prochaska; Philipp Wild; Manfred Beutel; Jörg Faber
Journal:  Cancer Med       Date:  2019-03-06       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.